CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Cefaclor

头孢克洛 杂质对照品Cefaclor Impurities

EP38 个杂质条目38 impurity entries

本页汇总 头孢克洛 的 38 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 38 impurity reference standards of Cefaclor with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 头孢克洛(Cefaclor)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesChromatographic studies of unusual on-column degradation of cefaclor observed in the impurity separation by HPLC
    Journal of pharmaceutical and biomedical analysis · 2019 · Zhong JS et al.  ·  PMID 31446297  ·  DOI
  2. 杂质研究Impurity studiesHPLC/ESI-MS identification of diastereomers of Impurity E - Degradation products of cefaclor
    Journal of pharmaceutical and biomedical analysis · 2020 · Chuchracka K et al.  ·  PMID 32814261  ·  DOI
  3. 杂质研究Impurity studiesChemical instability of cefaclor in simple suspensions alkalinized with magnesium oxide and the structural elucidation of the degradation products
    Journal of pharmaceutical sciences · 2026 · Kato G et al.  ·  PMID 41238187  ·  DOI
  4. 分析方法Analytical MethodsHPLC method development and validation for the determination of Cefaclor in human plasma
    Pakistan journal of pharmaceutical sciences · 2017 · Naz S et al.  ·  PMID 29084685

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisEnhanced enzymatic synthesis of a semi-synthetic cephalosprin, cefaclor, with in situ product removal
    Biotechnology letters · 2003 · Yang L, Wei DZ  ·  PMID 12967012  ·  DOI

头孢克洛 —— 原料药与杂质对照品Cefaclor — drug substance & impurities

共 39 个条目(含原料药本体)39 items incl. the drug substance
Cefaclor structure
EP原料药 APIAPI
头孢克洛Cefaclor
Cefaclor
CAS No.53994-73-3
Chemical FormulaC15H14ClN3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 1(Cefaclor EP Impurity A) structure
EPA
头孢克洛杂质1(头孢克洛EP杂质A)Cefaclor Impurity 1(Cefaclor EP Impurity A)
Cefaclor Impurity 1(Cefaclor EP Impurity A)
CAS No.875-74-1
Chemical FormulaC8H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 2(Cefaclor EP Impurity B) structure
EPB
头孢克洛杂质2(头孢克洛EP杂质B)Cefaclor Impurity 2(Cefaclor EP Impurity B)
Cefaclor Impurity 2(Cefaclor EP Impurity B)
CAS No.53994-69-7
Chemical FormulaC7H7ClN2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 3(Cefaclor EP Impurity C) structure
EPC
头孢克洛杂质3(头孢克洛EP杂质C)Cefaclor Impurity 3(Cefaclor EP Impurity C)
Cefaclor Impurity 3(Cefaclor EP Impurity C)
CAS No.143059-69-2
Chemical FormulaC15H14ClN3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 4 (Cefaclor EP Impurity D) structure
EPD
头孢克洛杂质4 (头孢克洛EP杂质D)Cefaclor Impurity 4 (Cefaclor EP Impurity D)
Cefaclor Impurity 4 (Cefaclor EP Impurity D)
CAS No.152575-13-8
Chemical FormulaC15H14ClN3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 5 (Cefaclor EP Impurity E) structure
EPE
头孢克洛杂质5 (头孢克洛EP杂质E)Cefaclor Impurity 5 (Cefaclor EP Impurity E)
Cefaclor Impurity 5 (Cefaclor EP Impurity E)
CAS No.2747959-02-8
Chemical FormulaC14H14ClN3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 7 (Cefaclor EP Impurity G) structure
EPG
头孢克洛杂质7 (头孢克洛EP杂质G)Cefaclor Impurity 7 (Cefaclor EP Impurity G)
Cefaclor Impurity 7 (Cefaclor EP Impurity G)
CAS No.67308-21-8
Chemical FormulaC16H17N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 9 structure
9
头孢克洛杂质9Cefaclor Impurity 9
Cefaclor Impurity 9
CAS No.142975-51-7
Chemical FormulaC30H26Cl2N6O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 10 structure
10
头孢克洛杂质10Cefaclor Impurity 10
Cefaclor Impurity 10
CAS No.188915-45-9
Chemical FormulaC15H14ClN3O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 11 structure
11
头孢克洛杂质11Cefaclor Impurity 11
Cefaclor Impurity 11
CAS No.53483-70-8
Chemical FormulaC14H12ClN3O5S·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 14 structure
14
头孢克洛杂质14Cefaclor Impurity 14
Cefaclor Impurity 14
CAS No.68506-27-4
Chemical FormulaC15H13ClN2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 15 structure
15
头孢克洛杂质15Cefaclor Impurity 15
Cefaclor Impurity 15
CAS No.55-21-0
Chemical FormulaC7H7NO
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 17 (Cefaclor Diketopiperazine) structure
17
头孢克洛杂质17 (头孢克洛二酮哌嗪)Cefaclor Impurity 17 (Cefaclor Diketopiperazine)
Cefaclor Impurity 17 (Cefaclor Diketopiperazine)
CAS No.188358-82-9
Chemical FormulaC15H14ClN3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 18 structure
18
头孢克洛杂质18Cefaclor Impurity 18
Cefaclor Impurity 18
CAS No.89-24-7
Chemical FormulaC9H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 19 structure
19
头孢克洛杂质19Cefaclor Impurity 19
Cefaclor Impurity 19
CAS No.1161012-23-2
Chemical FormulaC10H14N2O
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 24 structure
24
头孢克洛杂质24Cefaclor Impurity 24
Cefaclor Impurity 24
CAS No.51795-31-4
Chemical FormulaC8H10N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 28 structure
28
头孢克洛杂质28Cefaclor Impurity 28
Cefaclor Impurity 28
CAS No.21746-02-1
Chemical FormulaC10H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 29 structure
29
头孢克洛杂质29Cefaclor Impurity 29
Cefaclor Impurity 29
CAS No.833-40-9
Chemical FormulaC10H12N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 36 structure
36
头孢克洛杂质36Cefaclor Impurity 36
Cefaclor Impurity 36
CAS No.15028-39-4
Chemical FormulaC9H11NO2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 36 Monomer structure
36
头孢克洛杂质36 单体Cefaclor Impurity 36 Monomer
Cefaclor Impurity 36 Monomer
CAS No.37760-98-8
Chemical FormulaC9H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 37 structure
37
头孢克洛杂质37Cefaclor Impurity 37
Cefaclor Impurity 37
CAS No.2935-35-5
Chemical FormulaC8H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity C37 structure
C37
头孢克洛杂质C37Cefaclor Impurity C37
Cefaclor Impurity C37
CAS No.53994-83-5
Chemical FormulaC14H12ClN3O5S
Purity>95%现货In stock
10mg25mg50mg100mg
Cefaclor Impurity 38 structure
38
头孢克洛杂质38Cefaclor Impurity 38
Cefaclor Impurity 38
CAS No.24461-61-8
Chemical FormulaC9H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 42 structure
42
头孢克洛杂质42Cefaclor Impurity 42
Cefaclor Impurity 42
CAS No.2882-18-0
Chemical FormulaC10H8N2O
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 43 structure
43
头孢克洛杂质43Cefaclor Impurity 43
Cefaclor Impurity 43
CAS No.6453-64-1
Chemical FormulaC10H12N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 44 structure
44
头孢克洛杂质44Cefaclor Impurity 44
Cefaclor Impurity 44
CAS No.134624-91-2
Chemical FormulaC10H12N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 48 structure
48
头孢克洛杂质48Cefaclor Impurity 48
Cefaclor Impurity 48
CAS No.2832709-27-8
Chemical FormulaC20H20N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 51 structure
51
头孢克洛杂质51Cefaclor Impurity 51
Cefaclor Impurity 51
CAS No.220275-58-1
Chemical FormulaC8H10N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 52 structure
52
头孢克洛杂质52Cefaclor Impurity 52
Cefaclor Impurity 52
CAS No.131722-58-2
Chemical FormulaC8H10N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 53 structure
53
头孢克洛杂质53Cefaclor Impurity 53
Cefaclor Impurity 53
CAS No.79814-91-8
Chemical FormulaC16H17N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 56 structure
56
头孢克洛杂质56Cefaclor Impurity 56
Cefaclor Impurity 56
CAS No.122716-11-4
Chemical FormulaC16H19N3O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 57 structure
57
头孢克洛杂质57Cefaclor Impurity 57
Cefaclor Impurity 57
CAS No.65870-52-2
Chemical FormulaC16H17N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 63 structure
63
头孢克洛杂质63Cefaclor Impurity 63
Cefaclor Impurity 63
CAS No.39251-40-6
Chemical FormulaC10H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 66 structure
66
头孢克洛杂质66Cefaclor Impurity 66
Cefaclor Impurity 66
CAS No.768350-18-1
Chemical FormulaC16H17N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 67 structure
67
头孢克洛杂质67Cefaclor Impurity 67
Cefaclor Impurity 67
CAS No.33477-97-3
Chemical FormulaC15H14N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 68 structure
68
头孢克洛杂质68Cefaclor Impurity 68
Cefaclor Impurity 68
CAS No.36923-19-0
Chemical FormulaC28H24N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 76 structure
76
头孢克洛杂质76Cefaclor Impurity 76
Cefaclor Impurity 76
CAS No.188915-50-6
Chemical FormulaC14H14ClN3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 81 structure
81
头孢克洛杂质81Cefaclor Impurity 81
Cefaclor Impurity 81
CAS No.188915-49-3
Chemical FormulaC14H12ClN3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefaclor Impurity 82 structure
82
头孢克洛杂质82Cefaclor Impurity 82
Cefaclor Impurity 82
CAS No.722547-49-1
Chemical FormulaC17H18N2O3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

头孢克洛 —— 研究文献与合成路线Cefaclor — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 头孢克洛 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Cefaclor. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Chromatographic studies of unusual on-column degradation of cefaclor observed in the impurity separation by HPLC
    Zhong JS, Huang Y, Wan JZ, et al. · Journal of pharmaceutical and biomedical analysis · 2019 · 被引 4cited 4
  2. Chemical instability of cefaclor in simple suspensions alkalinized with magnesium oxide and the structural elucidation of the degradation products
    Kato G, Mitome H, Yamanaka M, et al. · Journal of pharmaceutical sciences · 2026 · 被引 1cited 1
  3. HPLC/ESI-MS identification of diastereomers of Impurity E - Degradation products of cefaclor
    Chuchracka K, Frański R, Frańska M · Journal of pharmaceutical and biomedical analysis · 2020
  4. Isolation and structure elucidation of the major degradation products of cefaclor formed under aqueous acidic conditions
    Baertschi SW, Dorman DE, Occolowitz JL, et al. · Journal of pharmaceutical sciences · 1997 · 被引 15cited 15
  5. Isolation and structure elucidation of the major degradation products of cefaclor in the solid state
    Dorman DE, Lorenz LJ, Occolowitz JL, et al. · Journal of pharmaceutical sciences · 1997 · 被引 13cited 13
  6. Isolation and structure elucidation of a novel product of the acidic degradation of cefaclor
    Baertschi SW, Dorman DE, Occolowitz JL, et al. · Journal of pharmaceutical sciences · 1993 · 被引 9cited 9

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE SYNTHESIS OF CEFACLOR
    MOODY HAROLD MONRO, DOOREN VAN THEODORUS JOHANNES · 公开号 KR20070090042KR20070090042 · 2007
  2. PROCESS FOR THE SYNTHESIS OF CEFACLOR
    MOODY HAROLD MONRO, DOOREN THEODORUS JOHANNES GODFRIED MARIA VAN · 公开号 MX2007007937MX2007007937 · 2007
  3. Process for the Synthesis of Cefaclor
    MOODY HAROLD M, DOOREN THEODORUS JOHANNES GOLDFRIED MARIA V · 公开号 US2008050771US2008050771 · 2008
  4. Process for the synthesis of cefaclor
    MONRO MOODY HAROLD, JOHANNES DOOREN VAN THEODORUS · 公开号 CN101090978CN101090978 · 2007
  5. PROCESS FOR THE SYNTHESIS OF CEFACLOR
    MOODY HAROLD MONRO, DOOREN VAN THEODORUS JOHANNES GODFRIED MARIA · 公开号 EP1831390EP1831390 · 2007

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

头孢克洛 杂质谱研究要点Cefaclor — impurity profiling notes

下面这些是拿到 头孢克洛 的 39 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 39 impurity entries for Cefaclor, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances